Other pharmacological treatments for motor complications and dyskinesias
Identifieur interne : 003811 ( Main/Exploration ); précédent : 003810; suivant : 003812Other pharmacological treatments for motor complications and dyskinesias
Auteurs : Cheryl Waters [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Amantadine (pharmacology), Amantadine (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Catechol O-Methyltransferase Inhibitors, Complication, Dopamine Agonists (therapeutic use), Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Gait (drug effects), Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Monoamine Oxidase (metabolism), Monoamine Oxidase Inhibitors (pharmacology), Monoamine Oxidase Inhibitors (therapeutic use), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Periodicity, Purinergic P1 Receptor Antagonists, Purines (pharmacology), Purines (therapeutic use), Selegiline (pharmacology), Selegiline (therapeutic use), Toxicity, Treatment, dyskinesias, motor complications, wearing‐off.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , metabolism : Monoamine Oxidase.
- chemical , pharmacology : Amantadine, Monoamine Oxidase Inhibitors, Purines, Selegiline.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Dopamine Agonists, Levodopa, Monoamine Oxidase Inhibitors, Purines, Selegiline.
- chemical : Catechol O-Methyltransferase Inhibitors, Purinergic P1 Receptor Antagonists.
- drug effects : Gait.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Humans, Periodicity.
Abstract
Controlling motor complications becomes increasingly difficult with disease progression. The “wearing‐off” phenomenon is the most‐common motor fluctuation. Wearing‐off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained‐release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol‐O‐methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter. The rotigotine constant‐delivery system is being developed to treat wearing‐off symptoms. Istradefylline (KW‐6002), an adenosine A2A receptor antagonist, has been studied for wearing‐off and the results will be discussed. The on–off fluctuations can be treated with liquid levodopa and the rescue therapy of injectable apomorphine. Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa–carbidopa, amantadine, and clozapine, an atypical neuroleptic. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20462
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001895
- to stream Istex, to step Curation: 001895
- to stream Istex, to step Checkpoint: 002218
- to stream PubMed, to step Corpus: 003082
- to stream PubMed, to step Curation: 003082
- to stream PubMed, to step Checkpoint: 003027
- to stream Ncbi, to step Merge: 001219
- to stream Ncbi, to step Curation: 001219
- to stream Ncbi, to step Checkpoint: 001219
- to stream Main, to step Merge: 004E95
- to stream PascalFrancis, to step Corpus: 001E71
- to stream PascalFrancis, to step Curation: 000E50
- to stream PascalFrancis, to step Checkpoint: 001D68
- to stream Main, to step Merge: 005246
- to stream Main, to step Curation: 003811
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Other pharmacological treatments for motor complications and dyskinesias</title><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:30267769EC05F10981667B757C1B5D0B6D435629</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20462</idno><idno type="url">https://api.istex.fr/document/30267769EC05F10981667B757C1B5D0B6D435629/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001895</idno><idno type="wicri:Area/Istex/Curation">001895</idno><idno type="wicri:Area/Istex/Checkpoint">002218</idno><idno type="wicri:doubleKey">0885-3185:2005:Waters C:other:pharmacological:treatments</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15822104</idno><idno type="wicri:Area/PubMed/Corpus">003082</idno><idno type="wicri:Area/PubMed/Curation">003082</idno><idno type="wicri:Area/PubMed/Checkpoint">003027</idno><idno type="wicri:Area/Ncbi/Merge">001219</idno><idno type="wicri:Area/Ncbi/Curation">001219</idno><idno type="wicri:Area/Ncbi/Checkpoint">001219</idno><idno type="wicri:doubleKey">0885-3185:2005:Waters C:other:pharmacological:treatments</idno><idno type="wicri:Area/Main/Merge">004E95</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0303503</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E71</idno><idno type="wicri:Area/PascalFrancis/Curation">000E50</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D68</idno><idno type="wicri:doubleKey">0885-3185:2005:Waters C:other:pharmacological:treatments</idno><idno type="wicri:Area/Main/Merge">005246</idno><idno type="wicri:Area/Main/Curation">003811</idno><idno type="wicri:Area/Main/Exploration">003811</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Other pharmacological treatments for motor complications and dyskinesias</title><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Movement Disorders, Department of Neurology, Columbia University, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S38">S38</biblScope><biblScope unit="page" to="S44">S44</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">30267769EC05F10981667B757C1B5D0B6D435629</idno><idno type="DOI">10.1002/mds.20462</idno><idno type="ArticleID">MDS20462</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (pharmacology)</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Complication</term><term>Dopamine Agonists (therapeutic use)</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Gait (drug effects)</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Monoamine Oxidase (metabolism)</term><term>Monoamine Oxidase Inhibitors (pharmacology)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Periodicity</term><term>Purinergic P1 Receptor Antagonists</term><term>Purines (pharmacology)</term><term>Purines (therapeutic use)</term><term>Selegiline (pharmacology)</term><term>Selegiline (therapeutic use)</term><term>Toxicity</term><term>Treatment</term><term>dyskinesias</term><term>motor complications</term><term>wearing‐off</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Monoamine Oxidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amantadine</term><term>Monoamine Oxidase Inhibitors</term><term>Purines</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term><term>Purines</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term><term>Purinergic P1 Receptor Antagonists</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gait</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Periodicity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Complication</term><term>Dyskinésie</term><term>Homme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Toxicité</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Controlling motor complications becomes increasingly difficult with disease progression. The “wearing‐off” phenomenon is the most‐common motor fluctuation. Wearing‐off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained‐release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol‐O‐methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter. The rotigotine constant‐delivery system is being developed to treat wearing‐off symptoms. Istradefylline (KW‐6002), an adenosine A2A receptor antagonist, has been studied for wearing‐off and the results will be discussed. The on–off fluctuations can be treated with liquid levodopa and the rescue therapy of injectable apomorphine. Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa–carbidopa, amantadine, and clozapine, an atypical neuroleptic. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region><settlement><li>New York</li></settlement><orgName><li>Université Columbia</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003811 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003811 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:30267769EC05F10981667B757C1B5D0B6D435629
|texte= Other pharmacological treatments for motor complications and dyskinesias
}}
| This area was generated with Dilib version V0.6.23. |  |